The possibility of treatment with ASOs that reduce pathogenic splice variants of C9orf72 is also under investigation for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.